Phase 2 Macular Degeneration Trial, Recruiting NCT06635148 Sponsor: Janssen Research & Development, LLC Condition: Macular Degeneration
Back to Macular Degeneration

Phase 2 Macular Degeneration Trial, Recruiting

NCT06635148
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have already taken part in one of two specific earlier studies (called 81201887MDG2001 or 81201887MDG1003) and received either the treatment JNJ-81201887 or a sham (inactive) procedure as part of that study
  • You must be willing to sign a consent form showing you understand what the study involves and agree to take part (in some cases, a witness or legal representative may sign on your behalf, depending on local rules)
  • Women who could become pregnant, men, and partners of male participants are not required to use contraception for this study

Who may not be able to join:

  • There are no specific exclusion criteria listed for this study — meaning the researchers have not identified any particular reasons that would automatically prevent someone from joining (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Phone: 844-434-4210

Australian sites

Centre for Eye Research Australia, East Melbourne,
Strathfield Retina Clinic, Strathfield,
Sydney Retina Clinic and Day Surgery, Sydney,
Sydney West Retina, Westmead,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
19 September 2024
Est. completion
24 August 2029

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇨🇦 Canada 🇨🇳 China 🇨🇿 Czechia 🇩🇰 Denmark 🇩🇪 Germany 🇭🇺 Hungary 🇮🇹 Italy 🇳🇱 Netherlands 🇵🇱 Poland 🇵🇹 Portugal 🇪🇸 Spain 🇸🇪 Sweden 🇨🇭 Switzerland Turkey (Türkiye) 🇬🇧 United Kingdom 🇺🇸 United States

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of Participants with Ocular and Systemic Treatment-emergent Adverse Events (TEAEs); Number of Participants with Abnormal Findings in Clinical Laboratory Assessments; Number of Participants with Abnormal Findings in Retinal imaging and Eye Examinations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov